Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 2Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5CNS 3Sarcoma 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Other 1NET 1Genitourinary 1Endocrine 1

Conditions

Smoldering Multiple Myeloma 3Multiple Myeloma 2

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Leflunomide × Plasma cell × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04370483 2026-01-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase EARLY_PHASE1 Active not recruiting
1 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT02509052 2023-10-10

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
12 enrolled 21 charts
Plasma cell

Multiple Myeloma

NCT03952832 2019-11-14

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡